JP2016503391A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503391A5
JP2016503391A5 JP2015538050A JP2015538050A JP2016503391A5 JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5 JP 2015538050 A JP2015538050 A JP 2015538050A JP 2015538050 A JP2015538050 A JP 2015538050A JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
fluoro
item
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503391A (ja
JP6385939B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065633 external-priority patent/WO2014063024A1/en
Publication of JP2016503391A publication Critical patent/JP2016503391A/ja
Publication of JP2016503391A5 publication Critical patent/JP2016503391A5/ja
Application granted granted Critical
Publication of JP6385939B2 publication Critical patent/JP6385939B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538050A 2012-10-19 2013-10-18 Mek阻害剤の調製およびmek阻害剤を含む製剤 Active JP6385939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716169P 2012-10-19 2012-10-19
US61/716,169 2012-10-19
PCT/US2013/065633 WO2014063024A1 (en) 2012-10-19 2013-10-18 Preparation of and formulation comprising a mek inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109486A Division JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤

Publications (3)

Publication Number Publication Date
JP2016503391A JP2016503391A (ja) 2016-02-04
JP2016503391A5 true JP2016503391A5 (2) 2016-12-01
JP6385939B2 JP6385939B2 (ja) 2018-09-05

Family

ID=50488781

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015538050A Active JP6385939B2 (ja) 2012-10-19 2013-10-18 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2018109486A Active JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2019149828A Pending JP2019194272A (ja) 2012-10-19 2019-08-19 Mek阻害剤の調製およびmek阻害剤を含む製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018109486A Active JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2019149828A Pending JP2019194272A (ja) 2012-10-19 2019-08-19 Mek阻害剤の調製およびmek阻害剤を含む製剤

Country Status (23)

Country Link
US (7) US9238627B2 (2)
EP (3) EP4306171A3 (2)
JP (3) JP6385939B2 (2)
CN (3) CN109456272A (2)
AR (1) AR099630A1 (2)
BR (1) BR112015008623B1 (2)
CA (2) CA3079071C (2)
CY (1) CY1122670T1 (2)
DK (2) DK2909182T3 (2)
ES (2) ES2772498T3 (2)
FI (1) FI3702351T3 (2)
HR (1) HRP20240033T1 (2)
HU (2) HUE047708T2 (2)
JO (1) JOP20130304B1 (2)
LT (1) LT3702351T (2)
PL (2) PL2909182T3 (2)
PT (2) PT2909182T (2)
RS (1) RS65117B1 (2)
RU (2) RU2669391C2 (2)
SI (2) SI2909182T1 (2)
SM (1) SMT202400044T1 (2)
TW (1) TWI650316B (2)
WO (1) WO2014063024A1 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3702351T3 (fi) * 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
EP3712133B1 (en) 2017-11-14 2025-12-24 Shenzhen TargetRx, Inc. Substituted benzimidazole compound and composition comprising same
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11395823B2 (en) * 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2023131976A1 (en) * 2022-01-06 2023-07-13 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
WO2024003942A1 (en) * 2022-07-01 2024-01-04 Natco Pharma Limited An improved process for the preparation of selumetinib sulfate
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
PL352835A1 (en) * 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2331246T3 (es) * 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
CA2612419C (en) 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
AU2006262375A1 (en) 2005-06-23 2007-01-04 Array Biopharma Inc. SNAr process for preparing benzimidazole compounds
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2007071951A1 (en) * 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
EA032294B1 (ru) * 2007-07-30 2019-05-31 Арди Байосайенсиз, Инк. Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
CA2761108A1 (en) 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
KR20140068037A (ko) 2011-09-01 2014-06-05 노파르티스 아게 누난 증후군의 치료를 위한 유기 화합물의 용도
FI3702351T3 (fi) 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus

Similar Documents

Publication Publication Date Title
JP2016503391A5 (2)
RU2015118572A (ru) Получение и составление композиции, содержащей ингибитор мек
CN101891738B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
JP6309057B2 (ja) ヒドラジド含有核輸送調節因子およびその使用
TWI749934B (zh) 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法
RU2581585C2 (ru) Способ получения 4-{4-[({[4-хлор-3-(трифторметил) фенил] амино}-карбонил) амино]-3-фторфенокси}-n-метилпиридин-2-карбоксамида, его солей и моногидрата
JP6267213B2 (ja) 5−(2,6−ジ−4−モルホリニル−4−ピリミジニル)−4−トリフルオロメチルピリジン−2−アミンを製造するための改良された方法
EP3672968B1 (en) Solid state form of ribociclib succinate
JP2010503694A5 (2)
TW201920196A (zh) 作為vanin抑制劑之雜芳族化合物
CN104936961A (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
EP2707367B1 (en) Methods for preparing naphthyridines
AU2007267612A1 (en) Preparation and utility of substituted carboxylic acid compounds
CN101967140A (zh) 氘代克里唑蒂尼及其衍生物、制备方法和应用
KR102660864B1 (ko) 에라바사이클린의 결정질 형태
WO2016074532A1 (zh) 艾立替尼的制备方法
CA2565629A1 (en) Process for preparing atazanavir bisulfate and novel forms
TW201831495A (zh) 製備細胞毒性苯二氮平衍生物之方法
CN102875634A (zh) 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102675395B (zh) 醋酸乌利司他的多晶型及其制备方法
TW202421625A (zh) 新穎sik抑制劑
KR20160068799A (ko) 신규 화합물
CN105315260A (zh) 一种托布司他一水合物晶型及其制备方法
CN102250084A (zh) 达沙替尼多晶型物及其制备方法和药用组合物
TW201041855A (en) New process for preparing